



PRESS RELEASE

PsychoGenics Extends its Drug Discovery Collaboration with Sunovion

TARRYTOWN, N.Y., September 14, 2015 – PGI Drug Discovery LLC (PsychoGenics), announced that the Company has extended its drug discovery and development collaboration with Sunovion Pharmaceuticals Inc. (Sunovion) for another four years.

In August 2007, PsychoGenics and Sunovion entered into a drug discovery and development agreement to combine their complementary strengths and expertise to screen compound libraries and identify a new generation of treatments for neuropsychiatric disorders. Since then the companies have expanded the scope of the collaboration, which has led to the identification of potential drug candidates including a compound in clinical development.

PsychoGenics' proprietary technologies combine broad *in vivo* behavioral expertise with robotics, computer vision, and bioinformatics to evaluate drug candidates for potential utility across the spectrum of Central Nervous System (CNS) disease indications. Working in partnership with pharmaceutical and biotech companies, PsychoGenics has been instrumental in helping to identify therapeutic potential for discontinued compounds, and early stage compounds with novel mechanisms of action.

About PsychoGenics

PsychoGenics is a leader in *in vivo* phenotypic drug discovery. The company applies its proprietary technology platforms in partnership with pharmaceutical and biotechnology companies to discover the next generation of drugs for neuropsychiatric disorders. PsychoGenics' capabilities also include standard behavioral testing, electrophysiology, molecular biology, and state-of-the-art microdialysis. In addition, the company offers a variety of in-licensed transgenic mouse models that support research in areas such as Huntington's disease, Autism spectrum disorders, psychosis/schizophrenia, Alzheimer's disease, Parkinson's disease, ALS, muscular dystrophy and other muscle disorders.

About Sunovion Pharmaceuticals Inc. (Sunovion)

Sunovion is a leading pharmaceutical company dedicated to discovering, developing and commercializing therapeutic products that advance the science of medicine in the Psychiatry, Neurology and Respiratory disease areas to improve the lives of patients and their families. Sunovion, an indirect, wholly-owned U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is headquartered in Marlborough, Mass. More information about Sunovion Pharmaceuticals Inc. is available at www.sunovion.com.

For more information contact:

Dr. Emer Leahy
President & CEO
Ph: (914) 406-8000
Email: info@psychogenics.com
www.psychogenics.com

